Eli Lilly and Company (LLY)
Eli Lilly's Weight Loss Drugs No Longer In Shortage. It's Bad News for These Stocks.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list.
Supply Issues Resolved for Eli Lilly's (LLY) Zepbound and Mounjaro
The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been resolved. This resolution may impact the market presence of generic versions that had become popular due to previous shortages.
Eli Lilly (LLY) Solves U.S. Shortage of Mounjaro and Zepbound, Plans Major Expansion
The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirzepatide, are now more readily available, patients and prescribers might still face occasional local shortages as they move through the supply chain.
US FDA says Lilly's weight-loss drug no longer in shortage
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday.
Eli Lilly CEO: We have 11 pipeline projects in obesity
CNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research and development center.
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly and Co LLY is making a major move with a $4.5 billion investment to create the Lilly Medicine Foundry, a new research and manufacturing facility.
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
Lilly announces new $4.5 bln manufacturing site in Indiana
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and drug development in Indiana.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Eli Lilly received FDA approval for Ebglyss for the treatment of moderate to severe atopic dermatitis this month. Ebglyss' efficacy looks comparable, if not slightly superior, to current market leader Dupixent. Ebglyss has launched successfully in Germany and Japan, and I expect the launch in the U.S. to go at least as well as Dupixent's launch in 2017.
This Is the Best Pharma Stock to Invest $1,000 in Right Now
Eli Lilly is making massive investments in manufacturing -- a key challenge now. The point of those investments is to produce enough of its drugs to meet demand.
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Eli Lilly and Novo Nordisk are spending billions to find new cardiometabolic drugs. Both companies are interested in the possibilities of genetic medicines.
